Clinical pathway on occupational medicamentosa-like dermatitis due to trichloroethylene
10.11763/j.issn.2095-2619.2017.04.004
- Author:
Qifeng WU
1
,
2
;
Lihua XIA
1
,
2
;
Zifang ZENG
1
,
2
;
Weihui LIANG
1
,
2
;
Bin LI
1
,
2
;
Yongshun HUANG
1
,
2
;
Cong LI
1
,
2
;
Hanlin HUANG
1
,
2
Author Information
1. Guangdong Province Hospital for Occupational Disease Provention and Treatment
2. Guangdong Province Key Laboratory of Occupational Disease Provention and Treatment Guangzhou,Guangdong 510300,China
- Publication Type:Journal Article
- Keywords:
Trichloroethylene;
Medicamentosa dermatitis;
Occupational disease;
Clinical pathway
- From:
China Occupational Medicine
2017;44(04):420-429
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To establish the clinical pathway of occupational medicamentosa-like dermatitis due to trichloroethylene(OMDT).METHODS: OMDT was selected as the clinical disease category.The diagnosis and treatment schemes of OMDT were determined and the clinical pathway was developed on the basis of evidence-based medicine,clinical data analysis,and the expert opinion as well as GBZ 185—2006 Diagnostic Criteria of Occupational Medicamentosa-like Dermatitis due to Trichloroethylene.The initial clinical validation was performed.RESULTS: We formulated the clinical pathway of OMDT for medical staffs,including standard hospitalization procedures(including normative use of glucocorticoids),Clinical Path Form,and Informed Consent for Glucocorticoid Therapy.The Clinical Pathway Notification of OMDT for patients or their family members was established.Based on the initial clinical verifications,the clinical pathway was conducive to optimize the medical process,none of the patients suffered from rebounds and complications,and the awareness of OMDT and satisfaction with treatments were improved.CONCLUSION: The clinical pathway for OMDT is scientific and reasonable,which is suitable for use to regulate medical behaviors.
